Design Therapeutics is initiated with a "Hold" rating as its lead candidate, DT-216P2 targets the ro

Wells Fargo analyst Tianqi Hang initiates coverage on Design Therapeutics (NASDAQ:DSGN) with a Ov

Design Therapeutics, Inc. (NASDAQ: DSGN - Get Free Report) has received an average recommendation of

Bank of New York Mellon Corp acquired a new position in shares of Design Therapeutics, Inc. (NASDAQ:

CARLSBAD, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a cli

BlackRock Inc. acquired a new position in Design Therapeutics, Inc. (NASDAQ: DSGN) during the undefi

U.S. stock futures mostly lower, Nasdaq 100 down 0.3%. Marvell Technology shares fall 7.6% after bea

An EV maker on the rebound, a Sun Belt landlord facing fresh headwinds, and a clinical-stage biotech

Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.32) per share which beat the anal

RESTORE-FA trial modifications build on positive four-week data; expect to share data based on 12 we

Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatmen

GeneTAC ® small molecule designed to selectively reduce transcription of the mutant DMPK allele and

Design Therapeutics has its proprietary GeneTAC platform. This gives them a small-molecule way to ta

CARLSBAD, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clini

TAT Technologies Ltd (TATT) reported better-than-expected Q1 results, sending shares up 11.7%. Other

Design Therapeutics Inc. (NASDAQ:DSGN) stock surged during the premarket session on Monday.

Design Therapeutics reported Phase 1/2 data for DT-216P2, showing biomarker and clinical improvement

Dow falls over 100 points, NASDAQ down 1.20% and S&P 500 down 0.64%. Energy shares surge, tech s

US stocks lower as Nasdaq falls 200 points, Dow down 0.04% and S&P 500 down 0.37%. Energy shares

Design Therapeutics, Inc. (DSGN) Discusses Data from RESTORE-FA Trial of DT-216P2 for Friedreich Ata

Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatment

DT-216P2 demonstrated dose-dependent improvement in multiple clinical measures and increases in endo

CARLSBAD, Calif. , May 17, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clin

Cramer likes Silicon Motion, whose shares fell 2.2% to settle at $263.85 on Thursday. Wynn shares de

Does Design Therapeutics, Inc. (DSGN) have what it takes to be a top stock pick for momentum investo

U.S. stock futures down 0.1%, Dole PLC drops 5.9% after missing earning estimates, other stocks also

Oppenheimer analyst Kostas Biliouris maintains Design Therapeutics (NASDAQ:DSGN) with a Outperfor

Design Therapeutics, Inc. (DSGN) Q1 2026 Earnings Call Prepared Remarks Transcript

Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.29) per share which beat the anal

Additional Detail Provided for RESTORE-FA (DT-216P2) Trial Design, Dosing and Endpoints David Shapir

Jefferies analyst Faisal Khurshid initiates coverage on Design Therapeutics (NASDAQ:DSGN) with a

RBC Capital analyst Leonid Timashev maintains Design Therapeutics (NASDAQ:DSGN) with a Outperform

Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.27) per share which beat the anal

Trials for DT-216P2 (RESTORE-FA) and DT-168 (FECD) Ongoing; DT-818 (DM1) Dosing in Patients Expected

Shares of Design Therapeutics, Inc. (NASDAQ: DSGN - Get Free Report) have received an average recomm

Oppenheimer analyst Trevor Allred initiates coverage on Design Therapeutics (NASDAQ:DSGN) with a

Leerink Partners analyst Joseph Schwartz upgrades Design Therapeutics (NASDAQ:DSGN) from Market P

RBC Capital analyst Leonid Timashev upgrades Design Therapeutics (NASDAQ:DSGN) from Sector Perfor

RBC Capital analyst Leonid Timashev maintains Design Therapeutics (NASDAQ:DSGN) with a Sector Per

Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.30) per share which beat the anal

Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatmen

https://news.bloomberglaw.com/health-law-and-business/fda-names-vinay-prasad-as-new-head-of-vaccines